Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma
Shots:
- The MHLW has approved Ezharmia (EZH1 & EZH2 inhibitor) to treat r/r peripheral T-cell lymphoma (PTCL) adults, supported by the P-II (VALENTINE-PTCL01) study
- VALENTINE-PTCL01 study assessed the safety & efficacy of Ezharmia to treat r/r PTCL (cohort 1) & ATLL (cohort 2) among patients (n=133) previously treated with systemic therapy & not suitable for HSCT
- In PTCL patients (n=119 patients), depicted an ORR of 43.7% with 17 CRs & 35 PRs. The patients with PTCL subtypes such as angioimmunoblastic T-cell lymphoma (AITL), PTCL not otherwise specified (PTCL-NOS) and others also responded. Data was highlighted at ASH 2023
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Submits sNDA for Ezharmia to the Japan MHLW for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
